351360-61-7

Basic information

• Product Name: (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER;TERT-BUTYL [(3S,4R)-4-PHENYLPYRROLIDIN-3-YL]CARBAMATE;TRANS-3-N-BOC-AMINO-4-PHENYLPYRROLIDINE;trans-(+/-)(4-Phenylpyrrolidin--yl)-carbamic acid;trans-(+/-)(4-Phenylpyrrolidin-3-yl)-carbamic acid;tert-Butyl N-[(3R,4S)-4-phenylpyrrolidin-3-yl]carbamate;-4-phenylpyrrolidin-3-yl);tert-Butyl ((3S,4R)
• CAS NO: 351360-61-7
• Molecular Formula: C15H22N2O2
• Molecular Weight: 262.35
• Mol File: 351360-61-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 401.1°C at 760 mmHg
• Flash Point: 196.4°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 1.21E-06mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.10±0.40(Predicted)
• CAS DataBase Reference: (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER(351360-61-7)
• EPA Substance Registry System: (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER(351360-61-7)

Safety Data

• Hazardous Substances Data: 351360-61-7(Hazardous Substances Data)

Usage

Description

(4-Phenylpyrrolidin-3-yl)carbamic acid tert-butyl ester is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical agents. It is characterized by its unique molecular structure, which includes a phenylpyrrolidine core and a carbamic acid tert-butyl ester group. (4-PHENYLPYRROLIDIN-3-YL)CARBAMIC ACID TERT-BUTYL ESTER plays a crucial role in the development of innovative therapeutics targeting specific enzymes.

Uses

Used in Pharmaceutical Industry:
(4-Phenylpyrrolidin-3-yl)carbamic acid tert-butyl ester is used as a chemical intermediate for the preparation of 3-amino-4-aryl-1-heteroarylpyrrolidines. These compounds are of significant interest due to their potential as inhibitors of dipeptidyl peptidase IV (DPP-IV), an enzyme involved in the regulation of glucose levels in the body. Inhibition of DPP-IV can lead to improved glucose tolerance and has been a target for the development of drugs to treat type 2 diabetes and other metabolic disorders.
In the synthesis of 3-amino-4-aryl-1-heteroarylpyrrolidines, (4-phenylpyrrolidin-3-yl)carbamic acid tert-butyl ester acts as a building block, providing the necessary structural elements for the formation of the final product. The development of these inhibitors can contribute to the advancement of novel therapeutic agents with improved efficacy and safety profiles for the treatment of diabetes and related metabolic conditions.

InChI:InChI=1/C15H22N2O2/c1-15(2,3)19-14(18)17-13-10-16-9-12(13)11-7-5-4-6-8-11/h4-8,12-13,16H,9-10H2,1-3H3,(H,17,18)/t12-,13+/m0/s1

Upstream product

• 1096341-35-3 trans-1-benzyl-4-phenylpyrrolidin-3-amine 
• 5153-67-3 nitrostyrene 
• 1096341-35-3 (±)-trans-1-benzyl-4-phenylpyrrolidin-3-amine 

Downstream Products

• 1414554-38-3 1-((3S,4R)-1-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea 
• 1414554-40-7 2-((3R,4S)-3-phenyl-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)ureido)pyrrolidin-1-yl)acetamide 

Relevant articles and documents

De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors

The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and b

N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.